The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. FILE PHOTO: Employees in advanced analytics work in the Express Scripts Technology and Innovation Lab building on Thursday ...

The health insurance giant Cigna said Thursday that it had agreed to buy Express Scripts, the nation’s largest pharmacy benefit manager, in a $52 billion deal that could further reshape the ...

Cigna signed a definitive agreement to acquire Express Scripts for $67 billion in cash and stock, including assumption of $15 billion in Express Scripts debt. Here are five things to know about ...

Cigna and Express Scripts will roll out the program by transferring covered insulin products to a lower copayment. The companies are working with insulin makers to lower copayments to $25.

Cigna subsidiary Express Scripts Inc. sued the Federal Trade Commission for defamation Tuesday, claiming FTC's report that pharmacy benefit managers have driven up prescription drug costs is false ...

News Cigna's Express Scripts Sues Federal Trade Commission "The FTC has taken unconstitutional actions in publishing a report that ignores the evidence provided by our company and other [pharmacy ...

Cigna has the most to lose: Express Scripts was responsible for 60% of the parent company's operating profit last year. That compares with 37% for CVS and Caremark and 16% for UnitedHealth and ...

Aug. 24--Shareholders of Cigna Corp. and Express Scripts Holding Co. voted Friday to approve the Bloomfield health insurer's $67 billion acquisition, pushing the megadeal closer to completion as a ...

The billionaire investor Carl Icahn is not a fan of Cigna's plan to purchase the pharmacy benefit manager Express Scripts, a $67 billion deal that was announced in March. In a letter to Cigna ...

Cigna's Express Scripts, one of the country's largest pharmacy benefit managers, today sued the Federal Trade Commission and its chair, Lina Khan, over what the company asserts was a report filled ...